Marker Therapeutics, Inc. (MRKR) Q1 2025 Annual Earnings
Marker Therapeutics, Inc. reported Q1 2025 revenue of $349.1K (-71.9% YoY), beat analyst consensus of $174.6K by $174.6K. Diluted EPS came in at $-0.27 (+0.0% YoY), beat the $-0.66 consensus by $0.39.
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Marker Therapeutics, Inc.'s Q1 2025 earnings report.
Marker Therapeutics, Inc. (MRKR) reported Q1 2025 earnings on May 21, 2025 before market open.
Marker Therapeutics, Inc. reported revenue of $349.1K and diluted EPS of $-0.27 for Q1 2025.
Revenue beat the consensus estimate of $174.6K by $174.6K. EPS beat the consensus estimate of $-0.66 by $0.39.
Compared to the same quarter a year prior, revenue declined 71.9% from $1.2M a year earlier and diluted EPS grew 0.0% from $-0.27.
You can read the 10-K periodic report (0001410578-25-000549) directly on SEC EDGAR. The filing index links above go to sec.gov.